Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Z Chang

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|June 7, 1996
A point mutation in interleukin-2 that alters ligand internalizationD Z Chang, Z Wu, T L Ciardelli
Molecular Pharmacology|January 1, 1995
Structural analogs of interleukin-2: a point mutation that facilitates biological responseD Z Chang, M L Tasayco, T L Ciardelli
Biochemistry|May 31, 1994
Mutagenic analysis of a receptor contact site on interleukin-2: preparation of an IL-2 analog with increased potencyW G Berndt, D Z Chang, K A Smith, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokineticsD Z Chang, T Olencki, G T Budd, et al.
British Journal of Cancer|July 12, 2012
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomasZ Meng, C R Garrett, Y Shen, et al.
Oncogene|September 22, 2015
LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cellsN Yokdang, J Hatakeyama, J H Wald, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|June 7, 1996
A point mutation in interleukin-2 that alters ligand internalizationD Z Chang, Z Wu, T L Ciardelli
Molecular Pharmacology|January 1, 1995
Structural analogs of interleukin-2: a point mutation that facilitates biological responseD Z Chang, M L Tasayco, T L Ciardelli
Biochemistry|May 31, 1994
Mutagenic analysis of a receptor contact site on interleukin-2: preparation of an IL-2 analog with increased potencyW G Berndt, D Z Chang, K A Smith, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokineticsD Z Chang, T Olencki, G T Budd, et al.
British Journal of Cancer|July 12, 2012
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomasZ Meng, C R Garrett, Y Shen, et al.
Oncogene|September 22, 2015
LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cellsN Yokdang, J Hatakeyama, J H Wald, et al.
Pageof 1